Achillion Pharmaceuticals, Inc.

246 articles with Achillion Pharmaceuticals, Inc.

• Achillion’s ACH-5228 Achieves Positive Results In Phase 1 Multiple Ascending Dose Study In Healthy Volunteers

  7/22/2019

  Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced results from their Phase 1 multiple ascending dose study with ACH-5228 outside of the United States.

• 

  BioSpace Movers and Shakers: Feb. 15

  2/15/2019

  Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.

• Achillion Appoints Brian Di Donato as Chief Financial Officer

  2/11/2019

  Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the appointment of Brian Di Donato to the position of Senior Vice President and Chief Financial Officer, effective immediately.

• 

  BioSpace Movers and Shakers: Jan. 4

  1/4/2019

  Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
• 

  Movers and Shakers for Sept. 17

  9/17/2018

  Let's take a look at some of the professionals moving to transition the pharma and biotech world this past week.
• 

  Achillion Slashes Staff and Initiates Restructuring Following Termination of J&J Deal

  2/22/2018

  Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan.

• Achillion Initiates Phase I First-in Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D

  12/20/2017

  This initial phase 1 trial is a randomized, placebo-controlled, single-ascending dose study of ACH-5228 administered to healthy volunteers.

• Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study

  12/18/2017

  This designation may provide, under specified conditions, for a seven-year marketing exclusivity period, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.

• Achillion Announces Pricing of Secondary Offering Of Common Stock

  11/16/2017

  The offering is expected to close on November 20, 2017, subject to the satisfaction of customary closing conditions.

• Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G

  11/15/2017

  Greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ACH-4471.

• Achillion Announces Proposed Secondary Offering of Common Stock

  11/15/2017

  Achillion will not sell any shares or receive any proceeds from the offering, and the total number of shares of its outstanding common stock will not change as a result of the offering.

• 

  Achillion's ACH-4471 is an Orphan Drug in the U.S. and Europe for PNH

  11/6/2017

  The EMA Committee for Orphan Medicinal Products also issued a positive opinion on ACH-4471 for orphan status in the European Union for the treatment of PNH.

• USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor

  10/24/2017

  This issued patent will be the eighth patent that the USPTO has granted to Achillion this year on its complement factor D portfolio.

• Achillion Announces Presentation of Data From OMEGA-1 Phase IIb Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting

  10/23/2017

  98.9% SVR12 achieved following six weeks of therapy for patients with chronic HCV genotypes 1, 2, 4, 5, or 6.

• Achillion Announces Strengthening Of Management Team

  9/11/2017

• Achillion Shares Surge on Promising ACH-4471 Phase II Data

  8/9/2017

• Achillion Reports Second Quarter 2017 Financial Results And Proof-Of-Concept With A First-In-Class, Oral Factor D Inhibitor

  8/9/2017

• Achillion To Host Second Quarter 2017 Results Conference Call On August 8, 2017

  8/2/2017

• Achillion Announces Key Promotion And Discovery Organization Change

  7/11/2017

• Achillion Reports First Quarter 2017 Financial Results And Provides Update On Clinical Programs

  5/4/2017